Mengis Capital Management, Inc. Biogen Inc. Transaction History

Mengis Capital Management, Inc.

$487 Million
Q2 2024

A detailed history of Mengis Capital Management, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Mengis Capital Management, Inc. holds 2,580 shares of BIIB stock, worth $448,378. This represents 0.12% of its overall portfolio holdings.

Number of Shares

2,580

Previous 2,580 -0.0%

Holding current value

$448,378

Previous $598,000 -0.0%

% of portfolio

0.12%

Previous 0.09%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$212.02 - $267.71 $1.16 Million - $1.47 Million	-5,475 Reduced 67.97%	2,580 $556,000
Q3 2023 Nov 09, 2023	SELL	$253.3 - $285.89 $12,665 - $14,294	-50 Reduced 0.62%	8,055 $2.07 Million
Q1 2023 May 05, 2023	BUY	$256.56 - $292.34 $2.08 Million - $2.37 Million	8,105 New	8,105 $2.25 Million
Q4 2022 Feb 01, 2023	SELL	$252.44 - $306.72 $2,524 - $3,067	-10 Reduced 0.12%	8,105 $2.24 Million
Q3 2022 Nov 04, 2022	SELL	$194.69 - $268.46 $350,442 - $483,227	-1,800 Reduced 18.15%	8,115 $2.17 Million
Q4 2021 Feb 04, 2022	SELL	$223.92 - $287.77 $612,421 - $787,050	-2,735 Reduced 21.62%	9,915 $2.38 Million
Q4 2020 Feb 03, 2021	SELL	$236.26 - $355.63 $1.39 Million - $2.1 Million	-5,900 Reduced 31.81%	12,650 $3.1 Million
Q3 2020 Oct 29, 2020	BUY	$264.77 - $305.71 $185,339 - $213,997	700 Added 3.92%	18,550 $5.26 Million
Q2 2020 Jul 22, 2020	BUY	$258.66 - $342.55 $2,845 - $3,768	11 Added 0.06%	17,850 $4.78 Million
Q1 2020 May 06, 2020	BUY	$268.85 - $341.04 $389,832 - $494,508	1,450 Added 8.85%	17,839 $5.64 Million
Q3 2019 Nov 05, 2019	BUY	$217.44 - $243.88 $241,358 - $270,706	1,110 Added 7.26%	16,389 $3.82 Million
Q2 2019 Jul 18, 2019	BUY	$219.29 - $241.72 $3.35 Million - $3.69 Million	15,279 New	15,279 $3.57 Million

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mengis Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Mengis Capital Management, Inc. with notifications on news.

Account

Mengis Capital Management, Inc. Biogen Inc. Transaction History